Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line  by Thum, Thomas et al.
Growth hormone induces eNOS expression and nitric oxide release in
a cultured human endothelial cell line
Thomas Thuma;b, Dimitris Tsikasb, Ju«rgen C. Fro«lichb, Ju«rgen Borlaka;
aFraunhofer Institute of Toxicology and Experimental Medicine (ITEM), Drug Research and Medical Biotechnology, 30625 Hannover, Germany
bInstitute of Clinical Pharmacology, Hannover Medical School, 30625 Hannover, Germany
Received 24 October 2003; accepted 5 November 2003
First published online 26 November 2003
Edited by Robert Barouki
Abstract Growth hormone de¢ciency is linked to cardiovascu-
lar disease and particularly increased peripheral vascular resis-
tance. Surprisingly, its role in endothelial nitric oxide (NO)
synthetase (eNOS) regulation and NO release is basically un-
known. We therefore studied the e¡ects of di¡erent doses of
somatotropin in cultures of a human endothelial cell line
(EAhy926). We investigated expression and activity of eNOS,
as well as other target genes known to be deregulated in car-
diovascular disease including E-selectin and the lectin-like oxi-
dized low density lipoprotein receptor. Treatment of cultured
human endothelial cells with somatotropin resulted in signi¢cant
(P6 0.05) increases of eNOS gene and protein expression, as
well as NO release, whereas production of intracellular reactive
oxygen species was signi¢cantly reduced, at the highest somato-
tropin dose level. The enhanced eNOS gene/protein expression
and enzyme activity correlate well. Our ¢ndings are suggestive
for a novel role of growth hormone in endothelial biology, and
particularly NO production.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Growth hormone (GH) might play an important role in
cardiovascular biology and indeed, growth hormone de¢-
ciency (GHD) is associated with risk for cardiovascular dis-
ease and increased peripheral vascular resistance [1]. Loss of
GH production in de¢cient patients leads to decreased sys-
temic nitric oxide (NO) levels and accelerated progression of
arteriosclerosis [1,2]. Consequently, treatment of patients with
recombinant GH (i.e. somatotropin) results in reduced total
peripheral resistance, enhanced cardiac output, as well as re-
duced plasma cholesterol concentrations [2,3]. GH also regu-
lates the synthesis of insulin-like growth factor (IGF-1), which
enhances release of NO as well [4].
Notably, little is known about the role of GH in the regu-
lation of endothelial NO synthetase (eNOS). We thus studied
the e¡ects of GH on the expression of eNOS and of other
target genes known to be deregulated in GHD and/or athero-
sclerosis, including genes encoding the adhesion molecules
ICAM-1, E-selectin, thrombomodulin, von Willebrand factor
(vWF), as well as endothelin-1, endothelin-converting enzyme
(ECE) and the lectin-like oxidized low density lipoprotein
(oxLDL) receptor (LOX-1) [5]. Further, free radicals react
with NO [6] and therefore, knowledge of intracellular reactive
oxygen production after treatment of endothelial cells with
increasing doses of recombinant GH is desirable. Overall,
we investigated the role of GH on endothelial NO production.
2. Materials and methods
2.1. Cell culture
EAhy926 cells were the kind gift of Dr. Edgell (University of North
Carolina at Chapel Hill, NC, USA) and are well characterized for
their endothelial biology [7]. Cells were cultured in six well plates
with Dulbecco’s modi¢ed Eagle’s medium supplemented with 10%
fetal calf serum (FCS) and L-glutamine (2 mM) until con£uence
(about 2 million cells/dish). At least 3 days after con£uence, medium
was changed to FCS-free DMEM and cells were immediately treated
with increasing doses of somatotropin (Pharmacia and Upjohn, Ger-
many; 10, 100, 1000 ng/ml) for 1^48 h and were harvested thereafter.
All experiments were done at least in triplicate.
2.2. Quality assurance
Cultured endothelial cells were examined by inverse phase contrast
microscopy before and after treatment with somatotropin (magni¢ca-
tion 20-fold). Expression of the endothelial-speci¢c membrane protein
platelet endothelial cell adhesion molecule-1 (PECAM-1) and viability
of endothelial cells by staining with propidium iodide was determined
by £uorescence-activated £ow cytometry, as described previously [8].
2.3. RNA and cDNA
RNA was isolated from endothelial cells using a total RNA Iso-
lation kit (Macherey-Nagel, Germany) according to the manufactur-
er’s recommendation. Quality and quantity of isolated RNA were
checked using capillary electrophoresis (Agilent Bioanalyzer 2100)
following the manufacturer’s instructions. 2 Wg total RNA from
each sample was used for reverse transcription, as described previ-
ously [9]. The resulting cDNA was frozen at 320‡C until further
experimentation.
2.4. Thermocycler reverse transcription polymerase chain reaction
(RT-PCR)
PCR reactions were carried out in a thermal cycler (T3, Biometra,
Germany) using the melting, annealing and extension cycling condi-
tions shown in Table 1. DNA contamination was checked for by
direct ampli¢cation of RNA extracts prior to conversion to cDNA.
Contamination of RNA extracts with genomic DNA could be ex-
cluded, as no template could be ampli¢ed. PCR reactions were done
within the linear range of ampli¢cation and ampli¢cation products
were separated using a 1.5% agarose gel and stained with ethidium
bromide. Gels were photographed on a transilluminator (Kodak im-
age station 440; see Fig. 1a) and amplicons were quanti¢ed using the
Kodak 1D 3.5 network software.
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2.5. Real-time semi-quantitative PCR
Real-time RT-PCR measurement were done with the Lightcycler
(Roche Diagnostics, Germany), as described previously [9]. Exact
quanti¢cation was achieved by a serial dilution with cDNA produced
from endothelial total RNA extracts using 1:5 dilution steps. Gene
expression levels were then given as the ratio of the gene of interest
(numerator) versus a well known housekeeping gene (cyclophilin A,
denominator).
2.6. Western immunoblotting
Cells were treated with somatotropin for 4 or 24 h (10^1000 ng/ml),
harvested, pelleted, and resuspended with Tris/Triton X lysis bu¡er
(1 mM Tris containing 0.1% Triton X (Sigma, Germany)). The cell
lysate was incubated for 45 min on ice and centrifuged for 15 min at
13 000Ug at 4‡C. Protein concentration was determined according to
Smith et al. [10] and the lysate was snap-frozen and stored at 380‡C
until further analysis. Western blotting was done as described previ-
ously [11] and a polyclonal eNOS antibody (Santa Cruz Biotechnol-
ogy, Germany, dilution 1:200) was used. Immunoreactive proteins
were visualized with a chemiluminescence reagent kit (NEN, Ger-
many) according to the manufacturer’s instructions, and bands were
scanned with the Kodak Image Station CF 440 and analyzed using
the Kodak 1D 3.5 imaging software (Eastman Kodak Company,
USA).
2.7. Intracellular reactive oxygen species (ROS) measurements
ROS measurements were done according to Royall et al. [12].
Brie£y, 2P,7P-dichloro£uorescein diacetate (DCFH-DA) di¡uses into
cells and is hydrolyzed into non-£uorescent DCFH. Intracellular ROS
oxidizes the non-£uorescent DCFH to highly £uorescent dichloro-
£uorescein. The increased £uorescent signal corresponds to ROS pro-
duction. After treatment of cell cultures with 10^1000 ng/ml somato-
tropin for 4 or 24 h, cells were incubated with 40 WM DCFH-DA for
30 min at 37‡C. Then, cells were harvested, centrifuged for 5 min at
4‡C and 1200 rpm, washed in phosphate-bu¡ered saline (PBS) and
resuspended with 800 Wl PBS bu¡er. After addition of propidium
iodide (1 Wg/ml), £uorescence emission was measured at 530S30 nm
(£uorescein) and 585S 42 nm (propidium iodide) after excitation of
cells at 488 nm using £ow cytometric analysis (Becton Dickinson,
USA).
2.8. Measurement of eNOS activity
Cells were treated for 4 or 24 h with 10^1000 ng/ml somatotropin.
Then, 15N-labelled arginine (5 mM) was added to culture media for
24 h and eNOS activity was assayed by determining the conversion of
L-[guanidino-15N]arginine to [15N]nitrite and [15N]nitrate using a val-
idated and established gas chromatography/mass spectrometry meth-
od [13].
2.9. Data analysis
Statistical signi¢cance was computed by analysis of variance fol-
lowed by a Wilcoxon signed rank test. Di¡erences were determined
to be signi¢cant at P6 0.05.
3. Results
3.1. Cell culture
Examination by phase contrast light microscopy did not
provide an indication for morphological changes or signs of
abnormalities in control or somatotropin-treated cell cultures.
In agreement with its morphological appearance, s 95% of
EAhy926 cells expressed PECAM-1. This is a well established
endothelial-speci¢c adhesion molecule and an accepted
marker for endothelial di¡erentiation [8]. Notably, treatment
of cultures with somatotropin did not change PECAM-1 ex-
pression and cell viability was s 98% in all treatment groups,
as judged by propidium iodide staining and £ow cytometry
analysis (data not shown).
3.2. Gene expression studies
We observed a statistically signi¢cant (P6 0.05) 1.9^2.3-
fold increase in eNOS gene expression after 4 h of somato-
tropin treatment (dose levels 100 and 1000 ng/ml). Dosing of
cell cultures with 10 ng/ml of somatotropin resulted in an up
to 2.5-fold (P6 0.05) induction 24 h post treatment (see Fig.
1b). No change in transcript levels of vWF, thrombomodulin,
endothelin-1, ECE, GH receptor (GHR) and IGF-1 receptor
was observed, but a dose-dependent and statistically signi¢-
cant (P6 0.05) reduction of E-selectin and LOX-1 gene ex-
pression to approximately 50% and 20% of control was noted
(Fig. 1a,c). Notably, inducible NOS (iNOS) mRNA expres-
sion was below the limit of detection, as was IGF-1K and
IGF-1L in total RNA extracts of EAhy926 cells. The latter
genes were strongly expressed in human liver, which served as
positive control (see Fig. 1a).
3.3. eNOS protein expression and enzyme activity
Protein expression of eNOS was increased in cells treated
with 10^1000 ng/ml somatotropin after 4 and 24 h of treat-
ment. In particular, eNOS protein expression peaked at 4 h
when the higher somatotropin dose level (100 or 1000 ng/ml)
was used, whereas dose levels of 10 ng/ml resulted in signi¢-
cantly enhanced protein expression after 24 h of treatment
(see Fig. 2a). Further, eNOS activity was determined by as-
saying conversion of L-[guanidino-15N]arginine to [15N]nitrite
and [15N]nitrate. Cultures treated with 1000 ng/ml of somato-
tropin resulted in signi¢cant (P6 0.05) 2.8-fold increases in
eNOS activity 4 h post treatment, whereas a three-fold in-
Table 1
Oligonucleotides used in gene expression studies
Accession number Gene Forward primer (5P-3P) Reverse primer (5P-3P) Length (bp) PCR cycles
NM_021130 cyclophilin tttcgtgctctgagcactgg cttgccattcctggacccaa 347 27
AF519768 eNOS gctgcgccaggctctcaccttc ggctgcagccctttgctctcaa 554 29
AF068236 iNOS cccttcaatggctggtacat ttttccaggcctctacctga 391 37
XM_006947 vWF gctgcagtatggaagcatca tcgtagcgatctccaattcc 300 29
M16552 thrombomodulin ccatgggagctggttagaaa agaccttgcagaccctgtgt 293 32
XM_165812 endothelin-1 ggcagagagctgtccaagtc ctgtttctggagctccttgg 355 34
NM_001397 ECE cttcctcgctggaagttttg gggtcatgctccactgatct 400 27
NM_000450 E-selectin agcccagagccttcagtgta aactgggatttgctgtgtcc 244 37
NM_002543 LOX-1 ttgctgcacacaatctagca cgagcatcaagatggagaca 394 36
XM_003896 GHR ctcaccaagctgcccatatt gccctgtggggactgtacta 419 37
NM_000875 IGF-1 receptor ggatgcggtgtccaataact tggcagcactcattgttctc 212 31
X56773 IGF-1K ggaggctggagatgtattgc actcgtgcagagcaaaggat 217 33
X56774 IGF-1L : tggatgctcttcagttcgtg gatgtgtctttggccaacct 294 36
PCR conditions: predenaturation 60 s, 95‡C, then denaturation 30 s, 94‡C, annealing 60 s, 55‡C, extension 60 s, 72‡C; ¢nal extension step
420 s, 72‡C.
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creased activity was determined after treatment with the 10
ng/ml dose 24 h post treatment (see Fig. 2b).
3.4. Intracellular ROS production
After 4 h of somatotropin treatment no change in intra-
cellular ROS production was noted at dose levels of 10 and
100 ng/ml, but an approximately 60% reduction was observed
in cultures of endothelial cells treated with 1000 ng/ml of
somatotropin. Twenty-four hours post treatment ROS pro-
duction was unchanged with the lower dose level (10 ng/ml),
but repressed to 80% and 40% of controls using the 100 and
1000 ng/ml dose levels, respectively (see Fig. 3).
4. Discussion
Patients with low levels of GH due to GHD have a reduced
NO availability [1,2]. GH replacement therapy of de¢cient
patients improved NO levels, recovered urinary nitrate and
cGMP production, lowered abnormally elevated vascular pe-
ripheral resistance and improved cardiac output [2]. Here, we
show somatotropin dosing of endothelial cells to result in
increased NO production through eNOS activation. Dosing
with somatotropin also repressed intracellular ROS produc-
tion, as detailed below.
There is evidence from animal models of heart failure for
Fig. 1. a: mRNA expression of GH receptor, E-selectin, LOX-1, cyclophilin, IGF-1K and IGF-1L in control and somatotropin (10, 100 and
1000 ng/ml; 24 h)-treated EAhy926 cells. b,c: Semiquantitative RT-PCR analysis. Gene expression of eNOS (b), endothelial-speci¢c proteins (c)
and GHR and IGF receptor (c) in human endothelial cells upon treatment with somatotropin (10, 100 and 1000 ng/ml; 24 h). Results are pre-
sented as ratios of gene of interest/cyclophilin in percent. Data represent meanSS.D. of n=3 di¡erent cultures with approximate 2 million cells
per culture dish. *P6 0.05.
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GH administration to improve cardiac function [14]. Simi-
larly, endothelium-dependent vascular function is also im-
proved after GH therapy in patients with diagnosed heart
failure [2]. There are additional clinical observations, which
show bene¢cial e¡ects of GH therapy in GHD, but no expla-
nation has been put forward.
Vasodilatory e¡ects of GH are mediated, at least in part, by
IGF-1. It was shown that activation of IGF-1 contributes to
enhanced NO release in cultured endothelial cells [4,15]. We
did not detect transcripts of IGF-1K and/or IGF-1L in cul-
tures of endothelial cells. The e¡ect of GH are therefore un-
likely to be mediated by local IGF production.
We observed dose- and time-dependent e¡ects of somato-
tropin on eNOS expression and activity. At the higher dose
levels (100^1000 ng/ml) we measured signi¢cantly enhanced
eNOS mRNA expression (P6 0.05, 1.9^2.3-fold; Fig. 1b),
protein expression (P6 0.05, 2.3^2.8-fold; Fig. 2a), whereas
NO levels in culture media were signi¢cantly increased only at
the highest dose level (P6 0.05, 2.6-fold; Fig. 2b). This dis-
crepancy can be explained by a dramatic reduction of ROS
production in endothelial cells treated with 1000 ng/ml soma-
totropin, whereas dosing with the lower levels (10^100 ng/ml)
had no e¡ect (Fig. 3). Therefore, the enhanced bioavailability
of NO after treatment with 1000 ng/ml for 4 h is likely the
result of both enhanced eNOS protein expression and reduced
ROS production. In strong contrast, we only observed signi¢-
cantly increased eNOS mRNA (P6 0.05, 2.3-fold, Fig. 1b)
and protein expression (P6 0.05, 2.1-fold, Fig. 2) in endothe-
lial cells treated for 24 h with low dose somatotropin (10 ng/
ml). Consequently, NO levels were highest (P6 0.05, 3.0-fold)
at this dose level (10 ng/ml). As detailed above, the bioavail-
ability of NO is dependent, at least in part, on production by
NOS and the presence of ROS, which can diminish NO in a
Fig. 2. a: Western immunoblotting of eNOS after treatment of cells with 10^1000 ng/ml of somatotropin for 4 h and 24 h. b: 15N/14N ratio of
nitrite after incubation of EAhy926 cells with [15N]arginine (5 mM) for 24 h. *P6 0.05.
Fig. 3. Flow cytometric analysis of intracellular ROS production in
control and somatotropin (10 to 1000 ng/ml, 4 and 24 h)-treated
EAhy926 cells. Control (4 h) was set to 100%. *P6 0.05.
FEBS 27918 8-12-03
T. Thum et al./FEBS Letters 555 (2003) 567^571570
reaction where peroxynitrite is formed [6]. We observed sig-
ni¢cantly reduced ROS levels in cells treated with higher so-
matotropin dose levels (100^1000 ng/ml; Fig. 3). Surprisingly,
at these dose levels NO availability was only slightly in-
creased, whereas a signi¢cant three-fold induction was ob-
vious at the 10 ng/ml dose. Again, ROS levels were not re-
duced at this particular dose. One explanation for the
observed e¡ect could be that the contribution of eNOS re-
garding total NO bioavailability is much higher than the
NO-consuming reaction with ROS. Further, we observed
transient and non-linear e¡ects of somatotropin regarding
eNOS expression and activity. This could be due to the
considerably short half-life of eNOS mRNA (90^360 min)
and protein (80^270 min), as recently shown by Ramet et
al. [16].
Arnold and Weigent [17] demonstrated overexpression of
GH in EL4 lymphoma cells to foster NO production as evi-
denced by enhanced iNOS protein expression, whereas eNOS
and nNOS protein expression were unchanged. Notably, we
did not observe similar ¢ndings in cultures of EAhy926 cells,
as somatotropin treatment resulted in enhanced eNOS expres-
sion and enzyme activity. Potentially, GH’s mode of action is
cell type-speci¢c. Further evidence stems from the study of
Wickman et al. [18], who show GH treatment of hypophysec-
tomized female rats to result in increased gene expression of
eNOS in endothelium of the aorta, but not in the heart. The
latter investigators did not, however, investigate eNOS activ-
ity or NO availability.
GH signaling is dependent on the level of GHR expression
[19]. So far, only two studies have been published on GHR
expression levels, in endothelial cells of ovarian vessels [20]
and capillaries of tumor tissue [21]. We report transcript levels
of GHR and of the IGF-1 receptor in a human endothelial
cell line, but did not observe a treatment-related e¡ect in the
gene expression of these receptors. The strong expression of
GHR observed in capillaries of liposarcoma [21] points to a
novel role of this receptor in tumor angiogenesis and there-
fore, GH therapy must be viewed with great caution.
Recently, Elhadd et al. reported GHD patients to carry
elevated plasma levels of vWF, ICAM-1, thrombomodulin
and E-selectin [5], which are accepted biomarkers of endothe-
lial dysfunction. We observed signi¢cant (P6 0.05) repression
of E-selectin mRNA levels after GH treatment. However, fur-
ther studies are needed to con¢rm the role of GH in the
pharmacotherapy of endothelial dysfunction.
Additionally, GH plays a major role in lipoprotein metab-
olism as therapy of GHD patients with somatotropin leads to
very signi¢cant repression of plasma LDL levels [2]. Further,
oxLDL can be internalized by endothelial-speci¢c LOX-1 and
enhanced levels of oxLDL result in upregulation of LOX-1
[22]. LOX-1 is therefore associated with the progression of
arteriosclerosis [22]. We observed a signi¢cant (P6 0.05) re-
duction of LOX-1 mRNA expression upon GH supplementa-
tion. We speculate for an important role of GH in the tran-
scriptional regulation of the oxLDL receptor and further
studies are on the way to investigate the potential cross-talk
between the GH and the LOX-1 receptor.
As detailed above, GHD patients su¡er from enhanced oxi-
dative stress [23], which is frequently accompanied by reduced
NO availability [6]. We show high dosing of cultured human
endothelial cells with GH to reduce intracellular ROS produc-
tion, presumably due to reduced metabolic deregulation and
improved antioxidative status. This is of importance as ROS
may diminish NO availability and may also alter expression of
eNOS [24]. Reduction of ROS production would provide an
additional bene¢t for GH therapy.
In conclusion, we provide evidence that GH up-regulates
eNOS expression and NO production in a cultured human
endothelial cell line. GH treatment resulted in reduced intra-
cellular ROS production, E-selectin and LOX-1 gene expres-
sion. This points to a novel role of GH in endothelial biology
and may provide the rationale for the increased risk in devel-
oping cardiovascular disease in patients with acquired GH
de¢ciency.
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